ReviewJournal of clinical medicine2024
Aggressive Types of Malignant Thyroid Neoplasms.
Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Diagnostic performance of machine learning and deep learning algorithms for thyroid cancer metastasis: a systematic review and meta-analysis.BMC medical informatics and decision making · 2025Pooled it
- Aggressive Thyroid Carcinomas Clinical and Molecular Features: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Clinical significance of coexisting Hashimoto's thyroiditis in differentiated thyroid cancer: a retrospective cohort study.BMC endocrine disorders · 2026Observational
- Construction and validation of a nomogram for predicting distant metastasis in Hurthle cell carcinoma of the thyroid.Updates in surgery · 2026Article
- The mechanism of fibronectin 1 promoting papillary thyroid cancer progression by regulating anoikis resistance.Scientific reports · 2026Article
- The tumor immune microenvironment of thyroid cancer and colorectal cancer: cellular crosstalk and therapeutic implications.Frontiers in immunology · 2026Review
- Clinicopathological, proliferative, molecular, and prognostic characteristics of differentiated high-grade thyroid carcinoma: a multicenter retrospective study.Frontiers in oncology · 2026Article
- Characteristics and outcome of pediatric and adult differentiated thyroid cancer with distant metastases.Frontiers in endocrinology · 2026Article
- Macrophage-Derived Transcriptional Signatures Predict Prognosis and Drug Sensitivity in Thyroid Cancer: Integrative Analysis and Experimental Validation of SMYD3.ImmunoTargets and therapy · 2026Article
- Vitamin D in Endocrine Disorders: A Broad Overview of Evidence in Musculoskeletal, Thyroid, Parathyroid, and Reproductive Disorders.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Diagnostic performances of five US risk stratification systems for malignancy in focal [European radiology · 2025Article
- Diagnostic Challenges, Prognostic Assessment, and Treatment Strategies in High-Grade Differentiated Thyroid Carcinoma.Endocrinology and metabolism (Seoul, Korea) · 2025Review
- Multilayered Insights into Poorly Differentiated,Diagnostics (Basel, Switzerland) · 2025Article
- Exploring the Public Awareness of Thyroid Cancer in Northern Saudi Arabia: A Preliminary Stage for Health Promotion.Healthcare (Basel, Switzerland) · 2025Article
- Multimodal spectrum of approach in poorly differentiated thyroid carcinoma (an updated analysis).Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
- In vitro Multi-targeted Anti-cancer Effects of Bavachinin in Papillary Thyroid Carcinoma Cell Line: Dual Pathway Inhibition and Cytokine Downregulation.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Differentiated thyroid cancer (DTC) includes many subtypes, which demonstrate favorable to aggressive behavior. During the past decades, efforts have been made to describe aggressive thyroid cancers. Within DTC, aggressive variants constitute rare entities with unique histopathological features and compromised survival, as local and distant metastatic disease is frequent. In recent years, the distinct category of poorly differentiated thyroid cancer was introduced in 2004 and the type of differentiated high-grade thyroid carcinoma was recently added in the 2022 WHO classification of thyroid neoplasms. Finally, anaplastic thyroid cancer exhibits a rapid, resistant to therapy, progression and confers the shortest survival. In this review, we will present the characteristics of these thyroid cancer types and also discuss the treatment, management, and follow-up of these difficult cases. Emphasis was given to recent bibliography of the last decade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.